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A
 
lthough the MHC is a key genetic component in au-
toimmune disease, our knowledge of the mechanisms
by which the molecules encoded within the MHC influ-
ence autoimmune processes remains incomplete. Because
of the linkage disequilibrium that exists among the class I,
II, and III genes within the HLA complex in humans and
the homologous MHC complex in rodents, the absolute
contribution of the individual loci has been difficult to dis-
sect. However, it is clear from association and linkage stud-
ies of autoimmune diseases in humans as well as from vari-
ous forms of analyses in the mouse and rat for diseases such
as spontaneous autoimmune diabetes and experimentally
induced encephalomyelitis, arthritis, and thyroiditis, that
class II molecules are a primary (but not always the sole)
basis of the HLA–MHC association. One area of intense
investigation and speculation has been stimulated by the
demonstration that particular class II molecules have posi-
tive, neutral, or negative association with human autoimmune
diabetes (1, 2).
Much of the experimental work to understand the con-
tribution of class II alleles to autoimmunity has used the
nonobese diabetic (NOD) mouse, a model of spontaneous
diabetes. Although analysis of the few intra-MHC recom-
binants available has pointed to the importance of the class
II region in autoimmune diabetes (3), transgenic introduc-
tion of class II molecules into the NOD mouse has pro-
vided the most persuasive evidence of the essential role of
particular class II molecules in the autoimmune process (4–
7). In addition, the disease diminution that has been af-
forded by the introduction of nondiabetogenic I-E or I-A
class II molecules has created models that are hoped to
mimic the protection observed in human autoimmune dia-
betes by certain HLA class II molecules that are negatively
associated with disease. However, the mechanism by which
the introduced nondiabetogenic class II molecules prevent
diabetes remains a point of controversy. Originally, one
leading hypothesis was that the introduced class II molecule
led to the deletion of self-reactive cells. However, evidence
to support this hypothesis was not found, leading several
groups to dismiss this possibility (8–12). In particular,
Mathis et al. (9) introduced by transgenesis into the NOD
 
mouse an islet-specific, I-A
 
g7
 
–restricted TCR derived from
a pathogenic clone, BDC2.5 (13). Such TCR-transgenic
NOD mice became diabetic with increased frequency and at
a somewhat earlier time than normal NOD mice. Intro-
 
duction of the E
 
a
 
 transgene, which protects NOD mice
from disease, failed to alter the disease course in the
BDC2.5 TCR-transgenic mice.
Other hypotheses were also put forth to explain the ex-
perimental results of disease protection. As reviewed by
Tisch and McDevitt (14), the presence or absence of an as-
partic acid at residue 57 of the 
 
b
 
 chain alters both the pep-
tide binding motif of a particular class II molecule as well as
its association with diabetes. This polymorphism would
therefore greatly influence the peptides presented during an
autoimmune response. Some studies documented a shift in
the balance of Th1 and Th2 in the presence of protective
class II molecules (14, 15). A different mechanism of dis-
ease association has been suggested by Unanue et al. who
have presented evidence that the I-A
 
g7
 
 molecule is rela-
tively unstable, which leads to poor peptide binding (16).
They hypothesized that such poor binding causes inade-
quate presentation of self peptides in the thymus, which
then leads to a greater number of self-reactive cells in the
periphery. Data consistent with this hypothesis have been
presented by Fathman et al. who observed an abnormal re-
activity to self proteins in NOD mice (17). Poor stability of
a diabetes-associated human class II molecule has also been
reported (18).
With these and many other studies not detailed here, the
stage is set for the study by Schmidt et al. (19) in the cur-
rent issue. Using a newly created TCR transgenic mouse,
the authors come to the surprising conclusion that thymic
deletion mediated by protective class II alleles, a mecha-
nism thought to have been ruled out previously, appears to
be a major factor in disease protection. The striking dispar-
ity between the current study and that described above (9)
where the TCR derived from the BDC2.5 T cell clone
was analyzed, may well be due to a difference in the mo-
lecular specificities of the two TCRs, both of which are
still unknown. Schmidt et al. use a TCR derived from a
pathogenic clone, NY4.1, isolated by Nagata and Yoon
(20). The NY4.1 transgenic mice display a more aggressive
disease course than the BDC2.5 transgenic mice, thus mak-
ing the reduction of insulitis and diabetes by disease-resis-
tant class II molecules even more striking. Other findings
detailed in the study suggest that non-MHC genes influ-
ence the development and activity of the transgenic T cells.
If this can be substantiated in further studies, the NY4.1
TCR may more closely represent the autoimmune T cells
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that are essential for the initiation and progression of disease
in the nontransgenic NOD mouse, T cells whose genera-
tion and activity are controlled by both MHC-linked and
non–MHC-linked diabetes-susceptibility loci (21). Such
non–MHC-linked loci might include genes that affect the
activation threshold of the T cells within the thymus and
the periphery, as well as genes which function in the many
pathways that result in the apoptosis of self-reactive cells.
Finally, hypotheses that attempt to explain the associa-
tion of the MHC with a particular autoimmune disease
must incorporate the fact that class II molecules are disease
specific. One particular class II allele is not associated with
many different autoimmune diseases, arguing that a diabe-
tes-associated allele, for example, does not produce a glo-
bally abnormal class II molecule, but rather encodes a func-
tional variant which somehow favors the production of
islet-specific T cells as compared with other alleles that are
not diabetes associated (22). The normal functionality of
disease-associated alleles is further emphasized by the fact
that disease-susceptible class II molecules cannot mediate
disease in the absence of additional non–MHC-linked sus-
ceptibility genes (23). One example of the ability of the
MHC to direct the autoimmune response in conjunction
with non-MHC autoimmune susceptibility genes is the sit-
uation where the B10.
 
H2
 
g
 
7
 
 (I-A
 
g7
 
) and B10.A(4R) (I-A
 
k
 
)
strains are both nonautoimmune, whereas the NOD (I-
A
 
g7
 
) and NOD.
 
H2
 
h
 
4
 
 (I-A
 
k
 
) strains are both autoimmune
prone but with different specificities. Although NOD mice
develop diabetes, only a small percentage of mice from this
strain display mild infiltrates of the thyroid gland. In con-
trast, NOD.
 
H2
 
h
 
4
 
 mice are free of diabetes (24), but display
extensive infiltration of the thyroid gland, especially in the
presence of increased dietary iodine (21, 25). The propen-
sity of NOD.
 
H2
 
h
 
4
 
 mice to develop thryoiditis is especially
interesting since I-A
 
k
 
 is the class II molecule required for
the induction of autoimmune thyroiditis after injection of
thyroglobulin (26). In addition, although the 
 
H2
 
b
 
 haplo-
type is protective in regard to diabetes (27), destructive si-
alitis leading to a diminution of secretory function is ob-
served in both NOD and NOD.
 
H2
 
b
 
 mice (28). Thus,
MHC-linked and non–MHC-linked genes act in concert
to cause a breakdown in tolerance: specific class II mole-
cules are necessary for the positive selection of what will
eventually be organ-specific pathogenic T cell clones (with
protective alleles potentially causing their deletion), whereas
the activity of products of non-MHC autoimmunity genes
enable these “forbidden clones” to escape normal tolerance
induction mechanisms that could potentially stop their de-
velopment into effectors of autoimmune destruction.
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